Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone × obinutuzumab × 30 days × Clear all

NCT06793189 2026-03-24

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Phase 2 Recruiting

Lymphoma, B-Cell, Marginal Zone